GeneReach Biotechnology (Taiwan) Performance
| 4171 Stock | TWD 28.95 0.05 0.17% |
The company retains a Market Volatility (i.e., Beta) of 0.0834, which attests to not very significant fluctuations relative to the market. As returns on the market increase, GeneReach Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding GeneReach Biotechnology is expected to be smaller as well. At this point, GeneReach Biotechnology has a negative expected return of -0.23%. Please make sure to check out GeneReach Biotechnology's jensen alpha, treynor ratio, and the relationship between the information ratio and total risk alpha , to decide if GeneReach Biotechnology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days GeneReach Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 313.7 M | |
| Total Cashflows From Investing Activities | -41.7 M |
GeneReach |
GeneReach Biotechnology Relative Risk vs. Return Landscape
If you would invest 3,355 in GeneReach Biotechnology on September 3, 2024 and sell it today you would lose (465.00) from holding GeneReach Biotechnology or give up 13.86% of portfolio value over 90 days. GeneReach Biotechnology is generating negative expected returns and assumes 1.1436% volatility on return distribution over the 90 days horizon. Simply put, 10% of stocks are less volatile than GeneReach, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
GeneReach Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GeneReach Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GeneReach Biotechnology, and traders can use it to determine the average amount a GeneReach Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2011
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 4171 |
Estimated Market Risk
| 1.14 actual daily | 10 90% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.2 actual daily | 0 Most of other assets perform better |
Based on monthly moving average GeneReach Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GeneReach Biotechnology by adding GeneReach Biotechnology to a well-diversified portfolio.
GeneReach Biotechnology Fundamentals Growth
GeneReach Stock prices reflect investors' perceptions of the future prospects and financial health of GeneReach Biotechnology, and GeneReach Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GeneReach Stock performance.
| Return On Equity | 0.3 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.38 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 2.09 B | |||
| Shares Outstanding | 45.97 M | |||
| Price To Earning | 8.39 X | |||
| Price To Book | 2.37 X | |||
| Price To Sales | 2.88 X | |||
| Revenue | 1.01 B | |||
| EBITDA | 535.64 M | |||
| Cash And Equivalents | 811.4 M | |||
| Cash Per Share | 17.65 X | |||
| Total Debt | 217.39 M | |||
| Debt To Equity | 0.30 % | |||
| Book Value Per Share | 24.36 X | |||
| Cash Flow From Operations | 348.99 M | |||
| Earnings Per Share | 6.90 X | |||
| Total Asset | 1.68 B | |||
About GeneReach Biotechnology Performance
Evaluating GeneReach Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if GeneReach Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GeneReach Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. GeneReach Biotechnology Corp. was founded in 2004 and is headquartered in Taichung, Taiwan. GENEREACH BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.Things to note about GeneReach Biotechnology performance evaluation
Checking the ongoing alerts about GeneReach Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GeneReach Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GeneReach Biotechnology generated a negative expected return over the last 90 days | |
| About 35.0% of the company shares are owned by insiders or employees |
- Analyzing GeneReach Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GeneReach Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining GeneReach Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GeneReach Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GeneReach Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GeneReach Biotechnology's stock. These opinions can provide insight into GeneReach Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for GeneReach Stock Analysis
When running GeneReach Biotechnology's price analysis, check to measure GeneReach Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneReach Biotechnology is operating at the current time. Most of GeneReach Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneReach Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneReach Biotechnology's price. Additionally, you may evaluate how the addition of GeneReach Biotechnology to your portfolios can decrease your overall portfolio volatility.